ALNYAlnylam Pharmaceuticals, Inc.

Price: $195.67 | Today's Change: -15.80%

What Happened

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K with the SEC on October 29, 2026, disclosing its financial results for the third quarter of fiscal year 2026 under Items 2.02 and 9.01. Revenue from contracts with customers for Q3 FY2026 came in at $2.617 billion, reflecting the company's significant commercial expansion. Despite reporting positive operating income of $369.9 million for the quarter, Alnylam recorded a net loss of $18.3 million, resulting in basic earnings per share of $1.55 and diluted EPS of $1.51 — a seeming contradiction that likely reflects below-the-line charges, tax effects, or non-operating items not fully detailed in the structured XBRL data provided.

Why It Matters

The headline revenue figure of $2.617 billion for a single quarter signals that Alnylam's commercial portfolio — anchored by its RNA interference (RNAi) therapies — has reached a scale that few rare-disease biotechs have achieved. The operating income of nearly $370 million confirms that the core business is generating meaningful profitability at the operating level. However, the thin net loss despite robust operating income raises an immediate question about what below-the-line costs are eroding earnings, and investors appear to be reacting negatively today, with shares falling 15.80%. Understanding the gap between operating income and net income will be critical for assessing the sustainability of Alnylam's profitability trajectory.

Note on EPS figures: The structured XBRL data reports basic EPS of $1.55 and diluted EPS of $1.51 alongside a net loss of -$18.3 million for Q3 FY2026. This apparent inconsistency may reflect reporting conventions, segment-level calculations, or adjustments within the XBRL tagging itself. Investors should refer to the full financial statements attached to the 8-K for reconciliation.

Analysis

This filing marks a significant commercial milestone for Alnylam — quarterly revenue crossing $2.6 billion puts the company firmly in large-cap biopharma territory in terms of revenue scale. StockWatch initiated coverage on ALNY on October 1, 2026; today's filing represents the first major earnings data point since that initiation, and the sharp intraday decline of nearly 16% suggests the market's reaction is mixed at best.

The key tension in this report is the disconnect between a healthy operating income (~$370 million) and a net loss (-$18.3 million). Investors and analysts will be scrutinizing:

• Non-operating items: Interest expense, collaboration agreement settlements, or investment losses that could explain the gap.
• Tax provisions: A significant deferred tax charge or valuation allowance adjustment could flip operating profitability to a net loss.
• Guidance and pipeline commentary: Any updates to full-year revenue expectations or clinical milestones for the broader RNAi pipeline will likely define the stock's next move more than the headline revenue beat.

The stock's sharp sell-off suggests the market may have been pricing in a cleaner net income positive print, or that forward guidance or pipeline news included in the earnings call disappointed. What to watch next: the full 10-Q filing and management's commentary on non-operating charges and the path to consistent GAAP net profitability.

Disclaimer

This report is provided for informational and news purposes only. It is based solely on data extracted from Alnylam Pharmaceuticals' SEC filing and associated XBRL data. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Past financial results are not indicative of future performance. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on ALNY, published 2026-10-01. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-29. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny-20261029.htm